| Field | Specification |
|---|---|
| Target | |
| Alternative names | 1-acylglycerol-3-phosphate O-acyltransferase ABHD5;2.3.1.51;Abhydrolase domain-containing protein 5;Lipid droplet-binding protein CGI-58;ABHD5;NCIE2;CGI-58; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E. coli-derived human Abhd5 recombinant protein (Position: R169-D349). Human Abhd5 shares 96.7% amino acid (aa) sequence identity with both mouse and rat Abhd5. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 in human, mouse and rat samples and is validated for ICC/IF, IHC and Western blot. The predicted molecular weight is 39.1 kDa, and the supplier reports an observed band at about 39 kDa.
ABHD5 (CGI-58) is the key coactivator of adipose triglyceride lipase (ATGL), controlling how fat stored in lipid droplets is broken down. It also shows lysophosphatidic acid acyltransferase activity, and its mutations cause Chanarin-Dorfman syndrome, a neutral lipid storage disease.
| Target | 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 (gene ABHD5; UniProt Q8WTS1, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 39.1 kDa |
| Observed MW | 39 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human, Mouse, Rat) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
Samples with a confirmed band (WB): human HeLa cells, human RT4 cells, human K562 cells, human HEL cells, rat testis tissue, mouse testis tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 10% SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human colon cancer tissue, human breast cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): HeLa cells.
Immunogen
Recombinant human Abhd5 fragment (Arg169–Asp349), expressed in E. coli. Sequence identity with the mouse and rat orthologs: 96.7%.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places 1-acylglycerol-3-phosphate O-acyltransferase ABHD5 in the cytoplasm. Tissue expression noted by UniProt (human): Widely expressed in various tissues, including lymphocytes, liver, skeletal muscle and brain. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
